But when the two drugs were combined in 12 patientswithadvancedlungcancer, tumors shrunk in 25% of the patients and stabilized in another 40%--much more impressive results than the two drugs produce alone.
Patientswithadvancedlung, kidney and skin cancer were among those who responded favorably, said Roy Herbst, an oncologist at Yale University, who headed the Roche study.